Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares 0 3 Month Treasury Bond ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while iShares 0 3 Month Treasury Bond ETF trades at $100.47. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | SGOV | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Fixed Income |
52-Week High | $28.06 | $100.74 |
52-Week Low | $20.06 | $100.28 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.44 with no daily change, reflecting its stable, cash-equivalent nature. Technical indicators signal a bearish trend from moving averages but neutral oscillators, while support and resistance cluster tightly at $100. The ETF offers a low 0.09% expense ratio and yields around 3.54–3.65%, attracting investors seeking short-term Treasury exposure amid rate uncertainty, as highlighted in recent financial news comparing it to peers like BIL.
The outlook for SGOV remains favorable for risk-averse investors prioritizing capital preservation and modest yield, with inflows into bond ETFs surging 60% year-over-year per CNBC (2026-06-25). Key risks include potential Fed rate hikes that could pressure short-term yields and inflation concerns, though its ultra-short duration minimizes interest rate sensitivity compared to longer bonds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
